Showing 1 - 7 results of 7 for search 'Guolin Yuan', query time: 0.03s Refine Results
  1. 1
    Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia

    Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia by Jingying Cui, Xuexing Chen, Chunfang Li, Qiong Yan, Guolin Yuan

    Published 2024-12-01
    Get full text
    Article
  2. 2
    Involvement of the arachidonic acid cytochrome P450 epoxygenase pathway in the proliferation and invasion of human multiple myeloma cells

    Involvement of the arachidonic acid cytochrome P450 epoxygenase pathway in the proliferation and invasion of human multiple myeloma cells by Jing Shao, Hongxiang Wang, Guolin Yuan, Zhichao Chen, Qiubai Li

    Published 2016-04-01
    Get full text
    Article
  3. 3
    Long-term outcomes of frontline imatinib therapy for chronic myeloid leukemia in China

    Long-term outcomes of frontline imatinib therapy for chronic myeloid leukemia in China by Fang Cheng, Fang Cheng, Fang Cheng, Guolin Yuan, Qiang Li, Qiang Li, Zheng Cui, Zheng Cui, Weiming Li

    Published 2023-05-01
    Get full text
    Article
  4. 4
    Development of a risk assessment model for cardiac injury in patients newly diagnosed with acute myeloid leukemia based on a multicenter, real-world analysis in China

    Development of a risk assessment model for cardiac injury in patients newly diagnosed with acute myeloid leukemia based on a multicenter, real-world analysis in China by Linlu Ma, Qian Wang, Xinqi Li, Yufeng Shang, Nan Zhang, Jinxian Wu, Yuxing Liang, Guopeng Chen, Yuxin Tan, Xiaoyan Liu, Guolin Yuan, Fuling Zhou

    Published 2024-01-01
    Get full text
    Article
  5. 5
    P666: 1 YEAR RESULTS OF DASATINIB 70MG/DAY VERSUS 100MG/DAY IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE(CML-CP):A PROSPECTIVE RANDOMIZED CONTROLLED STUDY.

    P666: 1 YEAR RESULTS OF DASATINIB 70MG/DAY VERSUS 100MG/DAY IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE(CML-CP):A PROSPECTIVE RANDOMIZED CONTROLLED S... by Dan Yu, Hui Cheng, Jingming Guo, Rui Jiang, Youshan Zhang, Chucheng Wan, Jun Qin, Guolin Yuan, Shiming Chen, Zhuangzhi Yang, Junbin Hu, Yicheng Zhang, Weiming LI

    Published 2023-08-01
    Get full text
    Article
  6. 6
    Zuberitamab, an innovative anti-CD20 monoclonal antibody, for patients with primary immune thrombocytopenia in China: a randomized, double-blind, placebo-controlled, phase 2 studyResearch in context

    Zuberitamab, an innovative anti-CD20 monoclonal antibody, for patients with primary immune thrombocytopenia in China: a randomized, double-blind, placebo-controlled, phase 2 studyR... by Min Xu, Jinhui Shu, Shenxian Qian, Jingming Guo, Yuping Gong, Ruibin Huang, Shuye Wang, Zeping Zhou, Guolin Yuan, Meijuan Huang, Li-E Lin, Shifeng Lou, Yanping Song, Qingchi Liu, Hu Zhou, Heng Mei, Yu Hu

    Published 2024-06-01
    Get full text
    Article
  7. 7
    Quality‐of‐life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia

    Quality‐of‐life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia by Yilin Chen, Na Xu, Yunfan Yang, Zhenfang Liu, Mengxing Xue, Li Meng, Qun He, Chunyan Chen, Qingshu Zeng, Huanling Zhu, Xin Du, Jing Zou, Wenjun He, Jingming Guo, Suning Chen, Guolin Yuan, Hui Wu, Mei Hong, Fanjun Cheng, Bingcheng Liu, Yanli Zhang, Weiming Li

    Published 2023-08-01
    Get full text
    Article

Search Tools: